On August 30, 2018 Otsuka America Pharmaceutical, Inc. (Otsuka) announced that it will collaborate with Magellan Health to bring the ABILIFY MYCITE® drug system to the United States. The ABILIFY MYCITE® system is a drug-device combination that is approved by the U.S. Food and Drug Administration (FDA). ABILIFY MYCITE® is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder, and for use as an add-on treatment for depression in adults. The system consists of the pill, a patch, an app for the consumer, and tools for health care . . .